AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01976936
Drug: Low Dose Lovastatin
RxNorm normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 80 mg daily for 3 days
Trial: NCT01976936
Drug: High Dose Lovastatin
RxNorm normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 640 mg daily for 3 days
Trial: NCT02170324
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01860287
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a within-subjects, double-blind, placebo-controlled experiment during which each participant will receive a placebo
Trial: NCT00642980
Drug: Clindamycin
RxNorm normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300 mg capsules (per os) Intervention= 2 capsules/d during 4 days: three times a month apart
Trial: NCT00642980
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double blinded capsules(per os) Intervention= 2 capsules/d during 4 days: three times a month apart
Trial: NCT00642980
Drug: Clindamycin
RxNorm normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300 mg capsules (per os) Intervention= 2 capsules/d during 4 days: one time and then, after one month placebo capsules 2 capsules/d during 4 days: two times a month apart
Trial: NCT02495129
Drug: VAY736 higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive a total number of 3 monthly subcutaneous injections with the higher dose of VAY736
Trial: NCT01151176
Drug: Regular Insulin
RxNorm normalized name: Regular insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,8U Regular insulin/h from 180mg/dL of blood glucose increasing each hour according to capillary blood glucose. Between 100-150mg/dL keep infusion and bellow 100mg/dL stop infusion
Trial: NCT01151176
Drug: Regular Insulin
RxNorm normalized name: Regular insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular Insulin SC according to Blood Glucose(mg/dL) and Insulin Sensitive with usual dose describe and less 2U for sensitive and plus 2U for insulin resistant:~Blood Glucose \>141-180=4U ;181-220=6U; 221-260=8U; 261-300=10U;301-350=12U; 351-400=14U; \> 400=16U
Trial: NCT03764462
Drug: AD-101 45mg
RxNorm normalized name: OXT-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene 45mg tablet
Trial: NCT02752880
Drug: YH1 group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants were randomly assigned 1:1 to receive either YH1 or placebo for 12 consecutive weeks.
Trial: NCT02752880
Drug: placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants were randomly assigned 1:1 to receive either YH1 or placebo for 12 consecutive weeks.
Trial: NCT02252146
Drug: IMO-8400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MO-8400 given subcutaneously twice weekly
Trial: NCT02488980
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for three days followed by placebo once a week for 24 weeks
Trial: NCT04333992
Drug: sevoflurane and remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inhalator sevoflurane and remifentanil using target-controlled infusion (TCI) devices
Trial: NCT01400776
Drug: WC3011 Estradiol Vaginal Cream
RxNorm normalized name: Estradiol Vaginal Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WC3011 estradiol vaginal cream administered once daily for 2 weeks followed by 2X/week or 3X/week for 10 weeks, total treatment duration 12 weeks
Trial: NCT01400776
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle administered once daily for 2 weeks followed by 2X/week or 3X/week for 10 weeks, total treatment duration 12 weeks.
Trial: NCT03648346
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo eye drops
Trial: NCT02797717
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ARM B , 25mg/m2
Trial: NCT02797717
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ARM A and ARM B , 625mg/m2 i.v
Trial: NCT00184041
Drug: Daunorubicin, Vincristine, Prednisone, Methotrexate, PEG-Asparaginase, 6-Mercaptopurine, Cytoxan, Cytosine Arabinoside, VM-26 and 6-Thioguanine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction I/II, consolidation I/II/III/IV and Maintenance
Trial: NCT04651881
Drug: Reference drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 Cap., single oral administration under fed condition
Trial: NCT04651881
Drug: Test drug 1
RxNorm normalized name: URINE TEST DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 Tab., single oral administration under fed condition
Trial: NCT04651881
Drug: Test drug 2
RxNorm normalized name: URINE TEST DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 Tab., single oral administration under fed condition
Trial: NCT04001413
Drug: MEDI0457
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI0457 is an investigational drug that will be administered with the Cellectra Device in this study
Trial: NCT02583919
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once weekly dosing for 26 weeks
Trial: NCT02566876
Drug: Mixture of three Bifidobacteria
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This investigation will be a randomized, double-blind, placebo-controlled, cross-over trial. The study will include 70 children with FD or IBS and will be articulated in 16 weeks as follows. Fifty-nine children (median age 11.2 years, range 5.2-17.9) with IBS and FD were randomized to receive either a mixture of three Bifidobacteria or a placebo for 6 weeks. At the end, after a 2-week-''washout'' period, each patient was switched to the other group and followed for 6 further weeks. At baseline and at follow-up, patients and/or their parents completed a dairy for bowel habit and gastrointestinal symptoms, and a quality of life (QoL) questionnaire.
Trial: NCT01210976
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nacl 0.9% coloured with thiamin in same volume and time than levosimendan
Trial: NCT00655538
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: po daily for 36 weeks
Trial: NCT03487731
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single administration of 1 cc of 1% lidocaine with 1 cc of 2% Ropivicaine and 0.5 cc of betamethasone soluspan (celestone) solution delivered via intra-facet injection.
Trial: NCT00481819
Drug: FK506MR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT00481819
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT00502736
Drug: ibandronate [Bondronat]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6mg iv on days 1-3
Trial: NCT00812877
Drug: Calcium Hydroxide
RxNorm normalized name: Calcium Hydroxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulp capping agent, Calcium Hydroxide
Trial: NCT00654368
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Commercially available methotrexate administed orally, subcutaneously or intramuscularly 15 mg/week (or 10 mg/week in case of documented intolerance to higher doses)
Trial: NCT01421017
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01364584
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection 2.5 mcg-10 mcg BID
Trial: NCT01439919
Drug: Placebo (for SSR411298)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Form: tablet~Route: oral administration with food
Trial: NCT02230735
Drug: Bipivacaine 0.5% with epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total of 14 ml of bupivacaine hydrochloride 0.5% with epinephrine 1:200,000, 7ml in right uterosacral ligament, 7ml in left uterosacral ligament
Trial: NCT02230735
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (placebo for bupivacaine)
Trial: NCT00254137
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03901131
Drug: Norethisterone enantate/estradiol valerate (Mesigyna, BAY98-7040)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Follow clinical administration
Trial: NCT03318835
Drug: R-CHOP
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rituximab 375 mg/m2,ivgtt D1 cyclophosphamide 750 mg/m2 iv D2 vincristine 1.4 mg/m2 \[capped at 2.0 mg\], iv D2 doxorubicin 50 mg/m2 iv D2 prednisone 100 mg/m2 per day PO D2-6
Trial: NCT02919774
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo tablets
Trial: NCT04557800
Drug: DNL151
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral dose(s)
Trial: NCT04557800
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral dose(s)
Trial: NCT00831272
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02249936
Drug: AZD1722
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00393848
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for Ketoconazole
Trial: NCT02013830
Drug: capecitabine [Xeloda]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1600mg/m2/day po in 2 divided doses, on days 1 to 14 of each 3 week cycle.
Trial: NCT02885805
Drug: BAY987516
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.00 mg/cm2 ± 0.04 mg/cm2
Trial: NCT02885805
Drug: SPF 15 Control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.00 mg/cm2 ± 0.04 mg/cm2
Trial: NCT01349335
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet, 30 mg, Qd, 7days.
Trial: NCT02686385
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04513548
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One injection every four weeks
Trial: NCT00001716
Drug: Nitric Oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02181309
Drug: Meloxicam, low dose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02181309
Drug: Meloxicam, medium dose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02181309
Drug: Meloxicam, high dose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01609517
Drug: Spinal anesthesia (heavy bupivacaine)
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal anesthesia with heavy bupivacaine of 6, 7, 8, 9, 10, 11 mg
Trial: NCT01064817
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution (0.1 mL volume) by subconjunctival injection Days 1 (immediately following trabeculectomy), 2, 3, 5 and 9
Trial: NCT00136058
Drug: alendronate or risedronate
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00006035
Drug: electroporation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01551056
Drug: AC-170 0.24%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop in each eye at 2 separate times during a 14 day period
Trial: NCT01551056
Drug: AC-170 0%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop in each eye at 2 separate times during a 14 day period
Trial: NCT00759161
Drug: AN2728
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AN2728 Ointment, 5%, twice daily for 4 weeks
Trial: NCT00759161
Drug: AN2728 Ointment Vehicle
RxNorm normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AN2728 Ointment Vehicle, twice daily for 4 weeks.
Trial: NCT00804986
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 of 5 volumes of placebo given once weekly for 12 weeks as a subcutaneous injection.
Trial: NCT01793441
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered in different stages of the study for 12 weeks.
Trial: NCT01793441
Drug: RG7314
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RG7314 will be administered orally at a dose of 1.5 mg/day in Stage I, 4 mg/day in Stage II, 10 mg/day in Stage III and 1.5 mg/day or 10 mg/day in Stage IV for 12 weeks.
Trial: NCT02832934
Drug: Levothyroxine
RxNorm normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects \<50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is \<0.4 mU/L, dose will be reduced by 25 mcg; TSH \>=0.4 and \<4.6 mU/L, no change to dose; TSH \>=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
Trial: NCT02832934
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug. Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg.
Trial: NCT01794000
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT00965081
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QD po at the same time each day for 12 weeks
Trial: NCT03700801
Drug: Triple combination therapy group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple oral hypoglycemic therapy based on metformin, dapagliflozin plus saxagliptin.
Trial: NCT00738699
Drug: 0.9% Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.9% normal saline) was administered by IV infusion weekly on Day 1 of Weeks 1 to 12 (Cycle 1) and then in 4-week cycles with treatment administered on Day 1 of Weeks 1 to 3 for all subsequent cycles.
Trial: NCT01744249
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally, twice daily, until disease progression or unacceptable toxicity, with or without food intake.
Trial: NCT02432326
Drug: BBI608
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The BBI608 starting dose is 240 mg twice daily (480 mg total daily). Dose will be decreased to 160 mg twice daily (320 mg total daily) at modification level 2 and 80 mg twice daily (160 mg total daily) at modification level 3. For BBI608 once daily dosing, doses at starting level and modification level 1 are 240 mg once daily, and 480 mg once daily at escalated levels. Dose will be decreased to 160 mg once daily at modification level 2 and 80 mg once daily at modification level 3.
Trial: NCT02432326
Drug: BBI503
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The BBI503 starting dose is 200 mg once daily. Dose at modification level 1 to 3 will be 100 mg once daily.
Trial: NCT01135134
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF Placebo nasal spray and administration will be as follows:~* 5 to 11 years: one spray per nostril once daily in the morning for 2 weeks~* 12 to 15 years: 2 sprays per nostril once daily in the morning for 2 weeks
Trial: NCT00407186
Drug: cisplatin+capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: cisplatin 20 mg/m2 (i.v., q 1 w, 5 weeks), capecitabine 575 mg/m2 (b.i.d., oral, on radiotherapy days.
Trial: NCT00407186
Drug: epirubicin+cisplatin+capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 courses q 3 w: epirubicin 50 mg/m2 (i.v., day 1), cisplatin 60 mg/m2 (i.v., day 1), capecitabine 1000 mg/m2 (b.i.d., oral, day 1-14)
Trial: NCT04030767
Drug: Botox Injectable Product
RxNorm normalized name: Botox Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin produces partial chemical denervation of the muscle resulting in localized reduction in muscle activity
Trial: NCT04033367
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous
Trial: NCT03020745
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is available as a Clear colorless solution.
Trial: NCT03679065
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each patient received a placebo tablet identical to paracetamol tablet orally with sips of water and 100 ml 0.9% NS IVI over 15 minutes as a placebo for Dex solution 2 hours preoperatively.
Trial: NCT03196310
Drug: Platelet Concentrate
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet Rich plasma
Trial: NCT00989937
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 IU BID or 40 IU BID
Trial: NCT03008161
Drug: NPT088
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgG1 Fc-GAIM fusion protein, a recombinant fusion protein
Trial: NCT03008161
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04537793
Drug: ELX/TEZ/IVA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose combination granules for oral administration.
Trial: NCT02057692
Drug: LUM001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LUM001 administered orally
Trial: NCT02057692
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered orally
Trial: NCT01727128
Drug: BKM120
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00860353
Drug: AZD2551
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of oral solution.
Trial: NCT00860353
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of oral solution
Trial: NCT02859246
Drug: Mucinex®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mucinex®
Trial: NCT02363855
Drug: BAY 1841788(ODM-201)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 1: Single dose 300 mg BAY 1841788, followed by twice daily administration of the same dose for 12 weeks Cohort 2: Single dose 2x300 mg BAY 1841788, followed by twice daily administration of the same dose for 12 weeks.
Trial: NCT02218684
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01994642
Drug: CIPRODEX® (ciprofloxacin 0.3%/dexamethasone 0.1%)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01994642
Drug: Placebo Sterile Otic Suspension
RxNorm normalized name: Otocort Sterile Suspension Otic Product
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01619839
Drug: NKTR-181
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01619839
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo dosing will be only in the double-blind randomization arm and will be identical in form to the Experimental NKTR-181
Trial: NCT03228771
Drug: PRGF/ATV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin loaded in PRGF fibrin scaffold
Trial: NCT03228771
Drug: ATV gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin loaded in methyl cellulose gel
Trial: NCT04610047
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsule
Trial: NCT01091831
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be given orally at the dose of 300 mg/m2 on days 1, 8, 15 for 6 cycles every 28 days
Trial: NCT03739710
Drug: GSK4428859A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK4428859A/EOS884448 will be administered.
Trial: NCT02111330
Drug: PBF-509
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02111330
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00002781
Drug: boronophenylalanine-fructose complex
RxNorm normalized name: Fructose
DrugBank: Fructose (DB04173)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03218384
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml of normal saline solution, and administered via volumetric infusion pump over 15 minutes.
Trial: NCT00329459
Drug: sumatriptan succinate/naproxen sodium
RxNorm normalized name: sumatriptan succinate/naproxen sodium 10 mg-60 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00329459
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo to match
Trial: NCT00814346
Drug: EGb761®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four weeks for AD patients, 18 months for MC and CNE patients